TNYA Earnings & Financial Statements
Tenaya Therapeutics, Inc.
$0.54
+$0.01(+2.02%)
33
Overall
60
Value
18
Tech
21
Quality
Market Cap
$119.60M
Volume
3.63M
52W Range
$0.53 - $2.35
Target Price
$9.33
TNYA earnings and financial statements: Tenaya Therapeutics, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
TNYA Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating income | -$93.33M | -$115.95M | -$131.19M | -$125.62M | -$72.81M |
| EBITDA | -$79.69M | -$99.27M | -$111.95M | -$119.15M | -$68.56M |
| Net income | -$90.60M | -$111.13M | -$124.08M | -$123.67M | -$72.70M |
| EPS (diluted) | $-0.59 | $-1.31 | $-1.68 | $-2.76 | $-4.10 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $146.92M | $119.94M | $170.51M | $278.94M | $314.19M |
| Total liabilities | $23.66M | $27.09M | $31.09M | $35.57M | $35.66M |
| Shareholders’ equity | $123.27M | $92.85M | $139.42M | $243.38M | $278.53M |
| Cash and equivalents | $100.55M | $4.32M | $45.68M | $95.27M | $38.13M |
| Long-term debt | $7.81M | $10.83M | $8.11M | $11.09M | $13.71M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$68.26M | -$90.50M | -$102.07M | -$104.42M | -$60.81M |
| Capital expenditure | -$618.0K | -$1.02M | -$1.24M | -$20.63M | -$25.12M |
| Free cash flow | -$68.88M | -$91.53M | -$103.31M | -$125.05M | -$85.93M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | TNYA | $0.54 | +2.0% | 3.63M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Tenaya Therapeutics, Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW